ExpreS2ion Announces Leadership Transition in R&D
Hørsholm, Denmark, 31 March 2025 - ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a pioneer in the development of innovative vaccines for a healthier world, today announced that Dr. Max Søgaard is promoted to Chief Science Officer, effective 1 April, taking over from Dr. Farshad Guirakhoo, who will continue in a consulting role as Senior Strategic Advisor Vaccine R&D.
Dr. Max Søgaard joined ExpreS2ion in 2013 and has been instrumental in advancing ExpreS2ion’s proprietary S2 technology ExpreS2, helping it reach its current status as a novel Phase III-proven platform. Most recently serving as Senior Vice President R&D and Technology, his leadership has been critical in the shaping the company’s R&D strategy and pipeline.
Dr. Max Søgaard commented on his promotion: “With our lead therapeutic breast cancer vaccine asset ES2B-C001 progressing in clinical Phase I, a robust pipeline of promising candidates addressing unmet needs in infectious diseases, and an innovative protein production platform, I am excited to take on the role as CSO. I look forward to continuing our mission to develop next-generation vaccines that can make a meaningful impact on global health.”
Bent Frandsen, Chief Executive Officer added: “Max’s deep scientific expertise and leadership make him the ideal choice to drive ExpreS2ion’s research and development efforts forward. I am confident that under his guidance, we will continue to innovate and advance our pipeline toward successful value trigger points.”
Bent Frandsen concluded: “I want to sincerely thank Farshad for his invaluable contributions over the past two years as CSO. His four decades of expertise in vaccine research and development have been instrumental in ExpreS2ion’s progress, and I am pleased that he will continue to provide strategic guidance in his new advisory role.”
For further information about ExpreS2ion, please contact:
Bent U. Frandsen, CEO
Keith Alexander, CFO
E-mail: investor@expres2ionbio.com
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
About ExpreS2ion
ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improve quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.
Tags: